We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Tiny Implantable Battery Shrinks Tumor Size By 99% In Two Weeks

By HospiMedica International staff writers
Posted on 30 May 2025

A groundbreaking biobattery has demonstrated its ability to reduce tumor growth and may offer a new, drug-free approach to immunotherapy treatment for cancer patients. More...

The tiny implantable biobattery, developed through a global collaboration between researchers at the University of Wollongong (UOW, NSW, Australia) and Jilin University (Changchun, China), successfully shrank tumors by 99% in just two weeks during laboratory tests. The research builds on the team's earlier advancements in biobattery technology, with these results showing strong potential for cancer treatment. Biobatteries share the same basic components as conventional batteries – two electrodes (anode and cathode), a separator, and an electrolyte – but instead of traditional electricity generation, they harness biological processes to produce power. Published in Science Advances, the study explores how these biobatteries can target tumors and trigger localized immune responses in the body. When the biobattery is activated, electrons are released from the anode and travel to the cathode, where they are consumed, accompanied by chemical reactions that stimulate the body's immune system.

When the biobattery was placed around subcutaneous tumor sites, those occurring between the skin and muscle, it reduced the tumor size from over 1,000 mm³ to just 4 mm³, a dramatic reduction of 99.6% in 14 days. The release of zinc and manganese ions played a crucial role in enabling the immune system to locate and destroy cancer cells. While the battery’s current alone is capable of slowing tumor growth, the targeted release of metal ions dramatically enhances the effect, stimulating immunotherapy – a potent and effective treatment for cancer. This breakthrough opens the door to treating tumors without relying on harsh drugs, which could minimize side effects and improve patients’ quality of life. The team’s next objective is to advance the biobattery through preclinical and clinical research to bring this innovation into clinical practice.

“In this research, the by-products of battery discharge – zinc and manganese ions – create a chemical environment that inhibits tumor growth,” said UOW Distinguished Professor Gordon Wallace. "If we are clever with electrode choice, biobatteries can be more effective in treating medical conditions, including mobilizing the body’s immune response and shrinking tumors.”

“This work demonstrates a powerful electrochemical tool for drug-free cancer immunotherapy, which may open an avenue for sustained and targeted delivery of substances that activate the immune system,” added Jia Xiaoteng, Associate Professor at Jilin University.

 


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
New
Knee Arthroscopy Holder
Reison 10-353 XL
New
High-Precision QA Tool
DEXA Phantom
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Surgical ablation could improve survival in patients with preexisting atrial fibrillation undergoing CABG (Photo courtesy of 123RF)

Surgical Ablation During CABG Improves Survival in Patients with Preexisting Atrial Fibrillation

Atrial fibrillation (AF) is a common condition among patients undergoing coronary artery bypass grafting (CABG). Surgical ablation for AF during CABG not only restores normal rhythm but may also reduce... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.